{"id":73810,"date":"2017-11-16T14:02:29","date_gmt":"2017-11-16T22:02:29","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2017\/11\/the-fda-just-approved-another-promising-immunotherapy-for-cancer"},"modified":"2017-11-16T14:02:29","modified_gmt":"2017-11-16T22:02:29","slug":"the-fda-just-approved-another-promising-immunotherapy-for-cancer","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2017\/11\/the-fda-just-approved-another-promising-immunotherapy-for-cancer","title":{"rendered":"The FDA Just Approved Another Promising Immunotherapy For Cancer"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/the-fda-just-approved-another-promising-immunotherapy-for-cancer.jpg\"><\/a><\/p>\n<p>On Wednesday\u2014for only the second time\u2014the <a href=\"https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm581216.htm\" target=\"_blank\" rel=\"noopener\">Food and Drug Administration approved<\/a> a cutting-edge therapy that genetically modifies a patient\u2019s blood cells in order to attack cancer. This time the therapy, known as CAR T-cell therapy, is designed to treat aggressive non-Hodgkin lymphoma.<\/p>\n<p>In August, <a href=\"https:\/\/gizmodo.com\/the-fda-just-approved-the-first-living-therapy-to-treat-1798629505\" rel=\"nofollow\">the FDA approved the first CAR T-cell therapy<\/a>, for a drug called Kymriah designed for children and young adults whose leukemia doesn\u2019t respond to standard treatments. The FDA\u2019s approval of Yescarta, manufactured by Kite Pharma, comes just a few months after its first approval\u2014an indication of just how quickly the field of immunotherapy is moving. Several other companies also have CAR-T therapies in the works.<\/p>\n<p><!-- Link: <a href=\"https:\/\/gizmodo.com\/the-fda-just-approved-another-promising-immunotherapy-f-1819682520#_ga=2.73893521.2024769426.1508251311-951680396.1494600478\">https:\/\/gizmodo.com\/the-fda-just-approved-another-promising-...1494600478<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On Wednesday\u2014for only the second time\u2014the Food and Drug Administration approved a cutting-edge therapy that genetically modifies a patient\u2019s blood cells in order to attack cancer. This time the therapy, known as CAR T-cell therapy, is designed to treat aggressive non-Hodgkin lymphoma. In August, the FDA approved the first CAR T-cell therapy, for a drug [\u2026]<\/p>\n","protected":false},"author":391,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412],"tags":[],"class_list":["post-73810","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/73810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/391"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=73810"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/73810\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=73810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=73810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=73810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}